Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20249274 | 0.76 | SLC6A2 (0.37) | — | |
| SCHEMBL20038208 | 0.76 | MKNK1 (0.36) | EP300MKNK1KDM1ACHRNB2CHRNA4 | |
| SCHEMBL18291461 | 0.76 | BCAT2 (0.39) | EP300MKNK1KDM1ACHRNB2CHRNA4 | |
| SCHEMBL20249296 | 0.76 | CHRNB2 (0.41) | KDM1ACHRNB2CHRNA4 | |
| SCHEMBL18291665 | 0.76 | CHRNB2 (0.35) | MKNK1KDM1ACHRNB2CHRNA4IRAK4 | |
| SCHEMBL14174627 | 0.73 | MAPT (0.43) | — | |
| SCHEMBL20249281 | 0.71 | — | — | |
| SCHEMBL20249279 | 0.69 | CHRNB2 (0.41) | MKNK1CHRNB2CHRNA4 | |
| SCHEMBL13094485 | 0.68 | NNMT (0.41) | — | |
| SCHEMBL29303910 | 0.68 | TP53 (0.46) | EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | EP300 1010/4885MKNK1 1165/4885KDM1A 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.